BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12692835)

  • 1. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.
    ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Meijer CJ
    J Pathol; 2003 May; 200(1):4-15. PubMed ID: 12692835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
    Benner MF; Jansen PM; Meijer CJ; Willemze R
    Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
    Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
    Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative.
    Kadin ME; Pinkus JL; Pinkus GS; Duran IH; Fuller CE; Onciu M; Kawaguchi H; Morris SW
    Am J Surg Pathol; 2008 Sep; 32(9):1421-6. PubMed ID: 18670345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.
    Rassidakis GZ; Sarris AH; Herling M; Ford RJ; Cabanillas F; McDonnell TJ; Medeiros LJ
    Am J Pathol; 2001 Aug; 159(2):527-35. PubMed ID: 11485911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?
    Fornari A; Piva R; Chiarle R; Novero D; Inghirami G
    Hematol Oncol; 2009 Dec; 27(4):161-70. PubMed ID: 19358142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.
    Weisenburger DD; Anderson JR; Diebold J; Gascoyne RD; MacLennan KA; Müller-Hermelink HK; Nathwani BN; Ullrich F; Armitage JO
    Am J Hematol; 2001 Jul; 67(3):172-8. PubMed ID: 11391714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations.
    Gjerdrum LM; Woetmann A; Odum N; Hother C; Henrik-Nielsen R; Gniadecki R; Ralfkiaer E
    Eur J Haematol; 2008 Jun; 80(6):483-9. PubMed ID: 18331599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic apoptotic pathway in anaplastic large cell lymphoma.
    Oyarzo MP; Drakos E; Atwell C; Amin HM; Medeiros LJ; Rassidakis GZ
    Hum Pathol; 2006 Jul; 37(7):874-82. PubMed ID: 16784988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation.
    Kinney MC; Kadin ME
    Am J Clin Pathol; 1999 Jan; 111(1 Suppl 1):S56-67. PubMed ID: 9894470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
    Herbst H; Sander C; Tronnier M; Kutzner H; Hügel H; Kaudewitz P
    Br J Dermatol; 1997 Nov; 137(5):680-6. PubMed ID: 9415224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease.
    Vermeer MH; Dukers DF; ten Berge RL; Bloemena E; Wu L; Vos W; de Vries E; Tensen CP; Meijer CJ; Willemze R
    Mod Pathol; 2002 Aug; 15(8):838-44. PubMed ID: 12181269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis.
    Gorczyca W; Tsang P; Liu Z; Wu CD; Dong HY; Goldstein M; Cohen P; Gangi M; Weisberger J
    Int J Oncol; 2003 Feb; 22(2):319-24. PubMed ID: 12527929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases.
    Kapur S; Tiemann M; Menke MA; Schubert C; Parwaresch R
    Indian J Med Res; 2005 Jan; 121(1):46-54. PubMed ID: 15713979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in survivin location and Bcl-2 expression in CD30+ lymphoproliferative disorders of the skin compared with systemic anaplastic large cell lymphomas: an immunohistochemical study.
    Goteri G; Simonetti O; Rupoli S; Piccinini G; Rubini C; Stramazzotti D; Fazioli F; Capomagi C; Leoni P; Offidani AM; Lo Muzio L
    Br J Dermatol; 2007 Jul; 157(1):41-8. PubMed ID: 17484779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY; Johnston PB; Burke KA; Zhao Y
    Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation.
    Sasaki K; Sugaya M; Fujita H; Takeuchi K; Torii H; Asahina A; Tamaki K
    Br J Dermatol; 2004 Jun; 150(6):1202-7. PubMed ID: 15214912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.
    Beylot-Barry M; Lamant L; Vergier B; de Muret A; Fraitag S; Delord B; Dubus P; Vaillant L; Delaunay M; MacGrogan G; Beylot C; de Mascarel A; Delsol G; Merlio JP
    Am J Pathol; 1996 Aug; 149(2):483-92. PubMed ID: 8701987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma.
    Lae ME; Ahmed I; Macon WR
    Am J Clin Pathol; 2002 Nov; 118(5):773-9. PubMed ID: 12428799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
    Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
    Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.